A novel intronic circular RNA circFGFR1int2 up-regulates FGFR1 by recruiting transcriptional activators P65/FUS and suppressing miR-4687-5p to promote prostate cancer progression
Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic...
Saved in:
Published in | Journal of translational medicine Vol. 21; no. 1; pp. 1 - 840 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central Ltd
22.11.2023
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of
FGFR1
due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1
int2
, derived from intron 2 of
FGFR1
gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1
int2
facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with
FGFR1
promoter. Moreover, we show that circFGFR1
int2
suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1
int2
is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (
RR
= 3.277, 95% confidence interval: 1.192–9.009;
P
= 0.021). These findings unravelled novel mechanisms controlling
FGFR1
gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target.
Graphic Abstract |
---|---|
AbstractList | Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1int2, derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (RR = 3.277, 95% confidence interval: 1.192–9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target.Graphic Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLC[gamma], and NF-?B. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1.sup.int2, derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1.sup.int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1.sup.int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1.sup.int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (RR = 3.277, 95% confidence interval: 1.192-9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target. Graphic Keywords: circRNA, FUS, P65, miRNA, FGFR1, Transcription regulation, Prostate cancer Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1int2, derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (RR = 3.277, 95% confidence interval: 1.192–9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target. Graphic Abstract Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1 int2 , derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1 int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1 int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1 int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) ( RR = 3.277, 95% confidence interval: 1.192–9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target. Graphic Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLC[gamma], and NF-?B. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1.sup.int2, derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1.sup.int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1.sup.int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1.sup.int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (RR = 3.277, 95% confidence interval: 1.192-9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target. Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1int2, derived from intron 2 of FGFR1 gene, which is overexpressed in PCa and associated with tumor progression. Importantly, we show that circFGFR1int2 facilitates FGFR1 transcription by recruiting transcription activators P65/FUS and by interacting with FGFR1 promoter. Moreover, we show that circFGFR1int2 suppresses post-transcriptional inhibitory effects of miR-4687-5p on FGFR1 mRNA. These mechanisms synergistically promote PCa cell growth, migration, and invasion. Overexpression of circFGFR1int2 is significantly correlated with higher tumor grade, Gleason score, and PSA level, and is a significant unfavorable prognosticator for CRPC-free survival (CFS) (RR = 3.277, 95% confidence interval: 1.192-9.009; P = 0.021). These findings unravelled novel mechanisms controlling FGFR1 gene expression by intronic circRNA and its potential clinicopathological utility as a diagnostic or therapeutic target. |
ArticleNumber | 840 |
Audience | Academic |
Author | Su, Zhengzheng Zhang, Mengni Zhou, Qiao Zhong, Jinjing Xu, Yunyi Wang, Ruyue Pan, Xiuyi Chen, Xueqin Chen, Ni Yu, Ting |
Author_xml | – sequence: 1 fullname: Wang, Ruyue – sequence: 2 fullname: Zhong, Jinjing – sequence: 3 fullname: Pan, Xiuyi – sequence: 4 fullname: Su, Zhengzheng – sequence: 5 fullname: Xu, Yunyi – sequence: 6 fullname: Zhang, Mengni – sequence: 7 fullname: Chen, Xueqin – sequence: 8 fullname: Chen, Ni – sequence: 9 fullname: Yu, Ting – sequence: 10 fullname: Zhou, Qiao |
BookMark | eNptUk1rGzEQXUoKTdL-gZ4EvfSyib61ezShTgMhLW5zFtqxZGTW0lbSBvy38gsr26FfFB1GM3rvjWZ4F81ZiME2zXuCrwjp5HUmtJeqxZS1mCvStftXzTnhqm9Fp-TZH_c3zUXOW4wpF7w_b54XKMQnOyIfSorBAwKfYB5NQquHxTFZ3i5XpD5TNE9tspv6WGxGxzIa9ihZSLMvPmxQSSZkSH4qPgYzIgPFP5kSU0ZfpbhePn5DJqxRnqcp2ZwPlJ1ftVx2qhUTKhFNKe5isYeYS-2DwASw6ZBvjpQY3javnRmzffcSL5vH5afvN5_b-y-3dzeL-xY4EaV1HKQE64QUdVZgzDpppeKOMCYxHthQl-AGAo4YLjl1ivZglKtk53An2GVzd9JdR7PVU_I7k_Y6Gq-PhZg22qTiYbSaDa5zDPCadpLLwfYdOOOoXPcGDwKrqvXxpFXn-DHbXPTOZ7DjaIKNc9a062nPJZGyQj_8A93GOdVtVlSPKWH1a_g3amNqfx9crLuHg6heKMU6JQShFXX1H1Q9a7vzUC3kfK3_RaAnAtT952Tdr7kJ1gen6ZPTdHWaPjpN79lPjKnIGg |
CitedBy_id | crossref_primary_10_1016_j_ncrna_2024_03_012 |
Cites_doi | 10.1016/j.gene.2009.03.004 10.1002/wrna.1338 10.1172/jci.insight.120594 10.1038/s41467-021-25082-9 10.1038/s41467-020-19381-w 10.1016/j.phrs.2019.104567 10.1101/gad.277137.115 10.1111/cas.15240 10.1038/s41467-023-40212-1 10.1186/s40478-020-00898-6 10.1210/en.2007-0114 10.1016/j.sbi.2019.07.012 10.1101/gad.204602.112 10.1091/mbc.e10-04-0290 10.1038/ng.2434 10.1016/j.tcb.2014.11.003 10.1038/s41556-021-00639-4 10.1074/jbc.M108411200 10.1038/nsmb.2959 10.1002/tox.23640 10.1016/j.canlet.2018.02.015 10.1016/j.jmb.2016.02.019 10.1038/s41419-019-2028-9 10.1016/j.it.2022.07.004 10.1152/physrev.00005.2020 10.1038/nrc2780 10.1016/j.canlet.2021.10.011 10.1158/1541-7786.MCR-17-0185 10.1111/cas.15694 10.1159/000335180 10.1002/med.21288 10.1016/j.gene.2007.06.010 10.1016/j.pharmthera.2020.107715 10.1007/s11060-021-03890-9 10.1016/j.celrep.2014.12.019 10.1038/s41418-018-0220-6 10.1186/s40478-020-01027-z 10.1016/j.bbcan.2021.188595 10.1371/journal.pmed.1002847 10.1038/ncomms14741 10.1038/s41586-021-03922-4 10.1016/j.yjmcc.2007.12.008 10.1158/0008-5472.CAN-22-3997 10.1111/jop.12773 10.1186/s12943-019-1111-2 10.1016/j.cell.2015.02.014 10.1128/mBio.01017-21 10.1126/scitranslmed.3009332 10.7554/eLife.40033 10.1074/jbc.M113.457648 10.1016/j.euo.2021.10.001 10.1016/S0140-6736(21)00950-8 10.1186/s13046-018-0813-4 10.1074/jbc.M011176200 10.1016/j.ejca.2021.04.005 10.1186/s13148-021-01212-4 10.1007/s00109-013-1077-2 10.3389/fmed.2022.861960 10.1158/0008-5472.CAN-13-1093 10.1016/j.celrep.2020.107641 10.1074/jbc.M113.493874 10.1017/S0022149X2000098X 10.1016/j.omtn.2019.01.003 10.1016/j.canlet.2022.01.016 10.1016/j.ando.2019.10.002 10.1038/s41467-019-12049-0 10.1016/j.molcel.2016.11.034 10.1158/2159-8290.CD-23-0004 10.1097/MPA.0000000000002119 10.1038/nature11993 10.1093/nar/gkaa035 10.1016/j.molcel.2021.07.042 10.1074/jbc.M410744200 10.1038/nrdp.2017.44 10.1038/onc.2011.140 10.1016/j.cell.2019.01.025 10.1038/s41571-021-00585-y 10.1016/j.ccell.2023.05.002 10.1016/j.neulet.2019.03.048 10.1186/s13059-014-0409-z 10.1158/1078-0432.CCR-14-3212 10.1186/s13073-018-0545-2 10.18632/oncotarget.2740 10.1186/s13046-020-01552-8 10.1016/j.yexcr.2009.08.008 10.1038/nrurol.2014.270 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | AAYXX CITATION 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 DOA |
DOI | 10.1186/s12967-023-04718-y |
DatabaseName | CrossRef ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts Immunology Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1479-5876 |
EndPage | 840 |
ExternalDocumentID | oai_doaj_org_article_3bf8f3c0d28646be98cfaf26d9a0b507 A773875512 10_1186_s12967_023_04718_y |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GroupedDBID | --- -A0 0R~ 29L 2WC 3V. 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACRMQ ADBBV ADINQ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M ABVAZ AFGXO AFNRJ 7T5 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c415t-f4c66cef565245c33ef6e674f133600b3b002fb1cf1a4642f729ca7f415ff0853 |
IEDL.DBID | BENPR |
ISSN | 1479-5876 |
IngestDate | Fri Oct 04 13:15:33 EDT 2024 Sat Aug 17 00:40:45 EDT 2024 Thu Oct 10 17:14:41 EDT 2024 Fri Feb 23 00:21:42 EST 2024 Fri Feb 02 04:35:55 EST 2024 Thu Sep 12 18:07:10 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c415t-f4c66cef565245c33ef6e674f133600b3b002fb1cf1a4642f729ca7f415ff0853 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-5133-1438 |
OpenAccessLink | https://www.proquest.com/docview/2902138530?pq-origsite=%requestingapplication% |
PQID | 2902138530 |
PQPubID | 43076 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_3bf8f3c0d28646be98cfaf26d9a0b507 proquest_miscellaneous_2892946166 proquest_journals_2902138530 gale_infotracmisc_A773875512 gale_infotracacademiconefile_A773875512 crossref_primary_10_1186_s12967_023_04718_y |
PublicationCentury | 2000 |
PublicationDate | 2023-11-22 |
PublicationDateYYYYMMDD | 2023-11-22 |
PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-22 day: 22 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Journal of translational medicine |
PublicationYear | 2023 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | SJ Conn (4718_CR88) 2015; 160 EP Carter (4718_CR7) 2015; 25 SB Zhang (4718_CR62) 2019; 10 DL Mitchell (4718_CR42) 2010; 316 EA Wellberg (4718_CR28) 2018; 3 N Javidi-Sharifi (4718_CR32) 2019; 8 S Sandhu (4718_CR1) 2021; 398 HG Vuong (4718_CR12) 2021; 155 Y Kong (4718_CR25) 2023; 83 E Labanca (4718_CR33) 2021; 5 M Armakola (4718_CR56) 2012; 44 W Liu (4718_CR19) 2019; 14 M Kanai (4718_CR38) 2009; 438 A Giacomini (4718_CR3) 2021; 101 O Bogatyrova (4718_CR27) 2021; 2021 D Orozco (4718_CR70) 2013; 91 LS Kristensen (4718_CR53) 2021; 19 X Wan (4718_CR84) 2014; 6 A Hopkins (4718_CR45) 2017; 15 KH Ho (4718_CR17) 2022; 113 AF Messmer-Blust (4718_CR39) 2012; 49 R Parakati (4718_CR41) 2013; 288 S Wang (4718_CR57) 2021; 12 JC Schwartz (4718_CR69) 2012; 26 CG Lucas (4718_CR13) 2020; 8 KQ Wang (4718_CR51) 2022; 51 M Musumeci (4718_CR16) 2011; 30 R Parakati (4718_CR43) 2002; 277 NO Tiryakioglu (4718_CR80) 2017; 77 L Errichelli (4718_CR87) 2017; 8 JU Guo (4718_CR22) 2014; 15 C Chu (4718_CR20) 2012; 61 W Wang (4718_CR79) 2020; 81 DL Mitchell (4718_CR40) 2010; 21 Y Chen (4718_CR64) 2019; 26 JR Brewer (4718_CR5) 2016; 30 TB Hansen (4718_CR75) 2013; 495 A Servetto (4718_CR34) 2021; 1876 TM Eidem (4718_CR59) 2016; 428 A Bronisz (4718_CR67) 2014; 289 M Seyed (4718_CR46) 2007; 400 Y Feng (4718_CR71) 2019; 10 S Terry (4718_CR82) 2015; 6 L Stoll (4718_CR63) 2020; 11 X Gao (4718_CR24) 2021; 23 S Chen (4718_CR6) 2019; 176 P Kaur (4718_CR9) 2022 Y Tang (4718_CR15) 2018; 37–52 Y Bao (4718_CR49) 2021; 13 Z Qu (4718_CR55) 2021; 12 J Zhong (4718_CR68) 2022; 530 CK Chen (4718_CR52) 2021; 81 FE Loughlin (4718_CR65) 2019; 59 V Mugoni (4718_CR86) 2022; 524 H Uranishi (4718_CR21) 2001; 276 PF Zhang (4718_CR50) 2019; 18 M McNicholas (4718_CR35) 2023; 13 T Lu (4718_CR37) 2018; 423 N Turner (4718_CR31) 2010; 10 HA Elmarakeby (4718_CR4) 2021; 598 C Thoma (4718_CR85) 2014; 11 H Li (4718_CR18) 2022; 37 A Masuda (4718_CR66) 2016; 7 A Panio (4718_CR81) 2022; 9 Z Su (4718_CR2) 2022; 114 F Saaoud (4718_CR76) 2021; 220 J Zhong (4718_CR26) 2023; 14 PJ O'Shea (4718_CR47) 2007; 148 G Stein-O'Brien (4718_CR14) 2018; 10 PR Pandey (4718_CR60) 2020; 48 M Katoh (4718_CR8) 2014; 34 R Parakati (4718_CR44) 2005; 280 B Mariz (4718_CR29) 2018; 47 L Chellini (4718_CR58) 2020; 39 M Katsu (4718_CR77) 2019; 708 R Roskoski Jr (4718_CR30) 2020; 151 JH Jeong (4718_CR74) 2017; 65 S Minisola (4718_CR11) 2017; 3 JL Carstens (4718_CR83) 2014; 74 G Di Timoteo (4718_CR89) 2020; 31 D Capece (4718_CR72) 2022; 43 TA Bale (4718_CR10) 2020; 8 M Seyed (4718_CR48) 2008; 44 S Orsten (4718_CR78) 2021; 95 T Helsten (4718_CR36) 2016; 22 Z Li (4718_CR54) 2015; 22 A Ivanov (4718_CR23) 2015; 10 VM Conn (4718_CR61) 2023; 41 AA Grosset (4718_CR73) 2019; 16 |
References_xml | – volume: 438 start-page: 49 issue: 1–2 year: 2009 ident: 4718_CR38 publication-title: Gene doi: 10.1016/j.gene.2009.03.004 contributor: fullname: M Kanai – volume: 7 start-page: 330 issue: 3 year: 2016 ident: 4718_CR66 publication-title: Wiley Interdiscip Rev RNA doi: 10.1002/wrna.1338 contributor: fullname: A Masuda – volume: 3 issue: 14 year: 2018 ident: 4718_CR28 publication-title: JCI Insight doi: 10.1172/jci.insight.120594 contributor: fullname: EA Wellberg – volume: 12 start-page: 4908 issue: 1 year: 2021 ident: 4718_CR57 publication-title: Nat Commun doi: 10.1038/s41467-021-25082-9 contributor: fullname: S Wang – volume: 11 start-page: 5611 issue: 1 year: 2020 ident: 4718_CR63 publication-title: Nat Commun doi: 10.1038/s41467-020-19381-w contributor: fullname: L Stoll – volume: 151 year: 2020 ident: 4718_CR30 publication-title: Pharmacol Res doi: 10.1016/j.phrs.2019.104567 contributor: fullname: R Roskoski Jr – volume: 30 start-page: 751 issue: 7 year: 2016 ident: 4718_CR5 publication-title: Genes Dev doi: 10.1101/gad.277137.115 contributor: fullname: JR Brewer – volume: 113 start-page: 540 issue: 2 year: 2022 ident: 4718_CR17 publication-title: Cancer Sci doi: 10.1111/cas.15240 contributor: fullname: KH Ho – volume: 14 start-page: 4467 issue: 1 year: 2023 ident: 4718_CR26 publication-title: Nat Commun doi: 10.1038/s41467-023-40212-1 contributor: fullname: J Zhong – volume: 8 start-page: 21 issue: 1 year: 2020 ident: 4718_CR10 publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-020-00898-6 contributor: fullname: TA Bale – volume: 148 start-page: 5966 issue: 12 year: 2007 ident: 4718_CR47 publication-title: Endocrinology doi: 10.1210/en.2007-0114 contributor: fullname: PJ O'Shea – volume: 59 start-page: 134 year: 2019 ident: 4718_CR65 publication-title: Curr Opin Struct Biol doi: 10.1016/j.sbi.2019.07.012 contributor: fullname: FE Loughlin – volume: 26 start-page: 2690 issue: 24 year: 2012 ident: 4718_CR69 publication-title: Genes Dev doi: 10.1101/gad.204602.112 contributor: fullname: JC Schwartz – volume: 21 start-page: 2780 issue: 15 year: 2010 ident: 4718_CR40 publication-title: Mol Biol Cell doi: 10.1091/mbc.e10-04-0290 contributor: fullname: DL Mitchell – volume-title: Leukemia year: 2022 ident: 4718_CR9 contributor: fullname: P Kaur – volume: 44 start-page: 1302 issue: 12 year: 2012 ident: 4718_CR56 publication-title: Nat Genet doi: 10.1038/ng.2434 contributor: fullname: M Armakola – volume: 25 start-page: 221 issue: 4 year: 2015 ident: 4718_CR7 publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2014.11.003 contributor: fullname: EP Carter – volume: 23 start-page: 278 issue: 3 year: 2021 ident: 4718_CR24 publication-title: Nat Cell Biol doi: 10.1038/s41556-021-00639-4 contributor: fullname: X Gao – volume: 277 start-page: 9278 issue: 11 year: 2002 ident: 4718_CR43 publication-title: J Biol Chem doi: 10.1074/jbc.M108411200 contributor: fullname: R Parakati – volume: 22 start-page: 256 issue: 3 year: 2015 ident: 4718_CR54 publication-title: Nat Struct Mol Biol doi: 10.1038/nsmb.2959 contributor: fullname: Z Li – volume: 37 start-page: 2832 issue: 12 year: 2022 ident: 4718_CR18 publication-title: Environ Toxicol doi: 10.1002/tox.23640 contributor: fullname: H Li – volume: 423 start-page: 36 year: 2018 ident: 4718_CR37 publication-title: Cancer Lett doi: 10.1016/j.canlet.2018.02.015 contributor: fullname: T Lu – volume: 428 start-page: 2652 issue: 12 year: 2016 ident: 4718_CR59 publication-title: J Mol Biol doi: 10.1016/j.jmb.2016.02.019 contributor: fullname: TM Eidem – volume: 10 start-page: 792 issue: 11 year: 2019 ident: 4718_CR71 publication-title: Cell Death Dis doi: 10.1038/s41419-019-2028-9 contributor: fullname: Y Feng – volume: 43 start-page: 757 issue: 9 year: 2022 ident: 4718_CR72 publication-title: Trends Immunol doi: 10.1016/j.it.2022.07.004 contributor: fullname: D Capece – volume: 101 start-page: 569 issue: 2 year: 2021 ident: 4718_CR3 publication-title: Physiol Rev doi: 10.1152/physrev.00005.2020 contributor: fullname: A Giacomini – volume: 10 start-page: 116 issue: 2 year: 2010 ident: 4718_CR31 publication-title: Nat Rev Cancer doi: 10.1038/nrc2780 contributor: fullname: N Turner – volume: 524 start-page: 57 year: 2022 ident: 4718_CR86 publication-title: Cancer Lett doi: 10.1016/j.canlet.2021.10.011 contributor: fullname: V Mugoni – volume: 15 start-page: 1341 issue: 10 year: 2017 ident: 4718_CR45 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-17-0185 contributor: fullname: A Hopkins – volume: 114 start-page: 1378 issue: 4 year: 2022 ident: 4718_CR2 publication-title: Cancer Sci doi: 10.1111/cas.15694 contributor: fullname: Z Su – volume: 49 start-page: 249 issue: 3 year: 2012 ident: 4718_CR39 publication-title: J Vasc Res doi: 10.1159/000335180 contributor: fullname: AF Messmer-Blust – volume: 34 start-page: 280 issue: 2 year: 2014 ident: 4718_CR8 publication-title: Med Res Rev doi: 10.1002/med.21288 contributor: fullname: M Katoh – volume: 400 start-page: 150 issue: 1–2 year: 2007 ident: 4718_CR46 publication-title: Gene doi: 10.1016/j.gene.2007.06.010 contributor: fullname: M Seyed – volume: 220 year: 2021 ident: 4718_CR76 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2020.107715 contributor: fullname: F Saaoud – volume: 155 start-page: 225 issue: 3 year: 2021 ident: 4718_CR12 publication-title: J Neurooncol doi: 10.1007/s11060-021-03890-9 contributor: fullname: HG Vuong – volume: 10 start-page: 170 issue: 2 year: 2015 ident: 4718_CR23 publication-title: Cell Rep doi: 10.1016/j.celrep.2014.12.019 contributor: fullname: A Ivanov – volume: 26 start-page: 1346 issue: 7 year: 2019 ident: 4718_CR64 publication-title: Cell Death Differ doi: 10.1038/s41418-018-0220-6 contributor: fullname: Y Chen – volume: 8 start-page: 151 issue: 1 year: 2020 ident: 4718_CR13 publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-020-01027-z contributor: fullname: CG Lucas – volume: 1876 issue: 2 year: 2021 ident: 4718_CR34 publication-title: Biochim Biophys Acta Rev Cancer doi: 10.1016/j.bbcan.2021.188595 contributor: fullname: A Servetto – volume: 16 issue: 7 year: 2019 ident: 4718_CR73 publication-title: PLoS Med doi: 10.1371/journal.pmed.1002847 contributor: fullname: AA Grosset – volume: 8 start-page: 14741 year: 2017 ident: 4718_CR87 publication-title: Nat Commun doi: 10.1038/ncomms14741 contributor: fullname: L Errichelli – volume: 598 start-page: 348 issue: 7880 year: 2021 ident: 4718_CR4 publication-title: Nature doi: 10.1038/s41586-021-03922-4 contributor: fullname: HA Elmarakeby – volume: 44 start-page: 510 issue: 3 year: 2008 ident: 4718_CR48 publication-title: J Mol Cell Cardiol doi: 10.1016/j.yjmcc.2007.12.008 contributor: fullname: M Seyed – volume: 83 start-page: 3077 issue: 18 year: 2023 ident: 4718_CR25 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-22-3997 contributor: fullname: Y Kong – volume: 47 start-page: 816 issue: 9 year: 2018 ident: 4718_CR29 publication-title: J Oral Pathol Med doi: 10.1111/jop.12773 contributor: fullname: B Mariz – volume: 18 start-page: 179 issue: 1 year: 2019 ident: 4718_CR50 publication-title: Mol Cancer doi: 10.1186/s12943-019-1111-2 contributor: fullname: PF Zhang – volume: 160 start-page: 1125 issue: 6 year: 2015 ident: 4718_CR88 publication-title: Cell doi: 10.1016/j.cell.2015.02.014 contributor: fullname: SJ Conn – volume: 12 issue: 4 year: 2021 ident: 4718_CR55 publication-title: mBio doi: 10.1128/mBio.01017-21 contributor: fullname: Z Qu – volume: 6 issue: 252 year: 2014 ident: 4718_CR84 publication-title: Sci Transl Med. doi: 10.1126/scitranslmed.3009332 contributor: fullname: X Wan – volume: 8 year: 2019 ident: 4718_CR32 publication-title: Elife doi: 10.7554/eLife.40033 contributor: fullname: N Javidi-Sharifi – volume: 77 start-page: P6 issue: 4 year: 2017 ident: 4718_CR80 publication-title: Cancer Res. contributor: fullname: NO Tiryakioglu – volume: 288 start-page: 13876 issue: 19 year: 2013 ident: 4718_CR41 publication-title: J Biol Chem doi: 10.1074/jbc.M113.457648 contributor: fullname: R Parakati – volume: 5 start-page: 164 issue: 2 year: 2021 ident: 4718_CR33 publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2021.10.001 contributor: fullname: E Labanca – volume: 398 start-page: 1075 issue: 10305 year: 2021 ident: 4718_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(21)00950-8 contributor: fullname: S Sandhu – volume: 37–52 start-page: 160 issue: 1 year: 2018 ident: 4718_CR15 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-018-0813-4 contributor: fullname: Y Tang – volume: 276 start-page: 13395 issue: 16 year: 2001 ident: 4718_CR21 publication-title: J Biol Chem doi: 10.1074/jbc.M011176200 contributor: fullname: H Uranishi – volume: 2021 start-page: 136 issue: 151 year: 2021 ident: 4718_CR27 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2021.04.005 contributor: fullname: O Bogatyrova – volume: 13 start-page: 228 issue: 1 year: 2021 ident: 4718_CR49 publication-title: Clin Epigenetics doi: 10.1186/s13148-021-01212-4 contributor: fullname: Y Bao – volume: 91 start-page: 1343 issue: 12 year: 2013 ident: 4718_CR70 publication-title: J Mol Med (Berl) doi: 10.1007/s00109-013-1077-2 contributor: fullname: D Orozco – volume: 9 year: 2022 ident: 4718_CR81 publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2022.861960 contributor: fullname: A Panio – volume: 74 start-page: 609 issue: 2 year: 2014 ident: 4718_CR83 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-1093 contributor: fullname: JL Carstens – volume: 61 start-page: 3912 year: 2012 ident: 4718_CR20 publication-title: J Vis Exp contributor: fullname: C Chu – volume: 31 issue: 6 year: 2020 ident: 4718_CR89 publication-title: Cell Rep doi: 10.1016/j.celrep.2020.107641 contributor: fullname: G Di Timoteo – volume: 289 start-page: 326 issue: 1 year: 2014 ident: 4718_CR67 publication-title: J Biol Chem doi: 10.1074/jbc.M113.493874 contributor: fullname: A Bronisz – volume: 95 start-page: 1 year: 2021 ident: 4718_CR78 publication-title: J Helminthol doi: 10.1017/S0022149X2000098X contributor: fullname: S Orsten – volume: 14 start-page: 609 year: 2019 ident: 4718_CR19 publication-title: Mol Ther Nucleic Acids doi: 10.1016/j.omtn.2019.01.003 contributor: fullname: W Liu – volume: 530 start-page: 68 year: 2022 ident: 4718_CR68 publication-title: Cancer Lett doi: 10.1016/j.canlet.2022.01.016 contributor: fullname: J Zhong – volume: 81 start-page: 18 issue: 1 year: 2020 ident: 4718_CR79 publication-title: Ann Endocrinol (Paris) doi: 10.1016/j.ando.2019.10.002 contributor: fullname: W Wang – volume: 10 start-page: 4119 issue: 1 year: 2019 ident: 4718_CR62 publication-title: Nat Commun doi: 10.1038/s41467-019-12049-0 contributor: fullname: SB Zhang – volume: 65 start-page: 154 issue: 1 year: 2017 ident: 4718_CR74 publication-title: Mol Cell doi: 10.1016/j.molcel.2016.11.034 contributor: fullname: JH Jeong – volume: 13 start-page: 1592 issue: 7 year: 2023 ident: 4718_CR35 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-23-0004 contributor: fullname: M McNicholas – volume: 51 start-page: 930 issue: 8 year: 2022 ident: 4718_CR51 publication-title: Pancreas doi: 10.1097/MPA.0000000000002119 contributor: fullname: KQ Wang – volume: 495 start-page: 384 issue: 7441 year: 2013 ident: 4718_CR75 publication-title: Nature doi: 10.1038/nature11993 contributor: fullname: TB Hansen – volume: 48 start-page: 3789 issue: 7 year: 2020 ident: 4718_CR60 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkaa035 contributor: fullname: PR Pandey – volume: 81 start-page: 4300 issue: 20 year: 2021 ident: 4718_CR52 publication-title: Mol Cell doi: 10.1016/j.molcel.2021.07.042 contributor: fullname: CK Chen – volume: 280 start-page: 21284 issue: 22 year: 2005 ident: 4718_CR44 publication-title: J Biol Chem doi: 10.1074/jbc.M410744200 contributor: fullname: R Parakati – volume: 3 start-page: 17044 year: 2017 ident: 4718_CR11 publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2017.44 contributor: fullname: S Minisola – volume: 30 start-page: 4231 issue: 41 year: 2011 ident: 4718_CR16 publication-title: Oncogene doi: 10.1038/onc.2011.140 contributor: fullname: M Musumeci – volume: 176 start-page: 831 issue: 4 year: 2019 ident: 4718_CR6 publication-title: Cell doi: 10.1016/j.cell.2019.01.025 contributor: fullname: S Chen – volume: 19 start-page: 188 issue: 3 year: 2021 ident: 4718_CR53 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-021-00585-y contributor: fullname: LS Kristensen – volume: 41 start-page: 1309 issue: 7 year: 2023 ident: 4718_CR61 publication-title: Cancer Cell doi: 10.1016/j.ccell.2023.05.002 contributor: fullname: VM Conn – volume: 708 year: 2019 ident: 4718_CR77 publication-title: Neurosci Lett doi: 10.1016/j.neulet.2019.03.048 contributor: fullname: M Katsu – volume: 15 start-page: 409 issue: 7 year: 2014 ident: 4718_CR22 publication-title: Genome Biol doi: 10.1186/s13059-014-0409-z contributor: fullname: JU Guo – volume: 22 start-page: 259 issue: 1 year: 2016 ident: 4718_CR36 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-3212 contributor: fullname: T Helsten – volume: 10 start-page: 37 issue: 1 year: 2018 ident: 4718_CR14 publication-title: Genome Med doi: 10.1186/s13073-018-0545-2 contributor: fullname: G Stein-O'Brien – volume: 6 start-page: 11994 issue: 14 year: 2015 ident: 4718_CR82 publication-title: Oncotarget doi: 10.18632/oncotarget.2740 contributor: fullname: S Terry – volume: 39 start-page: 51 issue: 1 year: 2020 ident: 4718_CR58 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-020-01552-8 contributor: fullname: L Chellini – volume: 316 start-page: 194 issue: 2 year: 2010 ident: 4718_CR42 publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2009.08.008 contributor: fullname: DL Mitchell – volume: 11 start-page: 604 issue: 11 year: 2014 ident: 4718_CR85 publication-title: Nat Rev Urol doi: 10.1038/nrurol.2014.270 contributor: fullname: C Thoma |
SSID | ssj0024549 |
Score | 2.4429238 |
Snippet | Abstract
Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including... Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2,... Abstract Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including... |
SourceID | doaj proquest gale crossref |
SourceType | Open Website Aggregation Database |
StartPage | 1 |
SubjectTerms | 1-Phosphatidylinositol 3-kinase AKT protein Analysis Antibodies Binding sites Care and treatment Cell migration Chromatin Chromosomes circRNA Circular RNA Development and progression Epigenetics Extracellular signal-regulated kinase FGFR1 Fibroblast growth factor receptor 1 Fibroblast growth factors Fibroblasts FUS Gene amplification Gene mutations Gene rearrangement Genetic aspects Health aspects Hybridization Kinases Medical prognosis MicroRNA miRNA Mutation NF-κB protein P65 Point mutation Post-transcription Prostate cancer Proteins Signal transduction Sperm Survival analysis Therapeutic targets Transcription factors Transcription regulation Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JL6ZO6SYMKgR6KWNuSZfu4DXVDIKFsu5CbsF6w0HqNH4H9W_2FnZHt0D2UXnoytiQsz4xmvsHzIOQCEEea6jJh0sYZE47XrJReM2NjnVhntQ553De38morru-yuz9afWFM2FQeeCLcimtfeG5imxZSSO3Kwvjap9KWdayzOY88yRZnaqmyB27PkiJTyFUPVg0UAtgnFqM2ZocjMxSq9f9NJwdDUz0jT2eESNfTzp6TR655QR7fzP_AX5Jfa9rs790Pumum_jXU7LoQTUo3t-twU32pNgkMp3RsWTd1m3c9DY-pPlDQct24w4BnOqCtWjQHvBbzHO7REe_pV5mtqu03WjeW9mM7RczCkp-7DRMStEbW0mFP2xDQ5_AaspOoQUHqaIj8mqp-vCLb6vP3yys2d15gBgz6wLwwUhrnAe0BKQ3nzksnc-HBowWEpDnadq8T45NagAfjAaKbOvew2HsAcfw1OWn2jXtDKDYzjkVd2DyTIva6FjEvrS6MtpjuZSPycWGEaqcCGyo4JoVUE9sUsE0FtqlDRD4hrx5mYnHs8ABERs0io_4lMhH5gJxWeISByqaeMxFgw1gMS63znIMbB1AoImdHM-HomePhRVbUfPR7lZYAmzjQII7I-4dhXInhbI3bjzCnAFQqZCLl2__xQafkSYqynSQsTc_IydCN7h1gpUGfh2PxG2ioEl8 priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9RAFB5qBfFFvGJslREEH2RskpmdTR5EVnEtwhZZXejbkLnJQk3SXIr7t_yFnjNJKgvVp5C5JGHO7TvkXAh5BYgjTXWeMGnjGROOFyyXXjNjY51YZ7UOedyrM3m6EV_OZ-cHZGp3NB5ge6Nrh_2kNs3F21-Xu_cg8O-CwGfypAWbBeIO1ofFqGvZ7ha5nQoukONXIvtbew-coSlx5sZ9e8Yp1PD_l6YO5md5n9wbcSNdDIR-QA5c-ZDcWY1_xh-R3wtaVlfugm7LoasNNdsmxJjS9dki3Cw_L9cJTKe0r1kz9KB3LQ3DVO8o6L6m32IYNO3Qgk36BF6L2Q9X6J639KucnSw332hRWtr29RBHC1t-btdMSNAls5p2Fa1DmJ_Da8hZogbZq6EhHmyoBfKYbJafvn88ZWM_BmbAzHfMCyOlcR4wIByl4dx56eRcePBzATdpjhbf68T4pBDg13gA7qaYe9jsPUA7_oQcllXpnhKKLY5jUWR2PpMi9roQMc-tzoy2mARmI_JmIoSqh7IbKrgrmVQD2RSQTQWyqV1EPiCtrldiyewwUDU_1CiBimufeW5im2ZSSO3yzPjCp9LmRawBFUfkNVJaIavBKZtizE-AD8YSWWoxn3Nw7gAgReR4byUIpNmfnnhFTfys0hzAFIcziCPy8noad2KQW-mqHtZkgFWFTKR89v9HHJG72PUeUyLT9Jgcdk3vngM26vSLwPB_AA_5DG8 priority: 102 providerName: Scholars Portal |
Title | A novel intronic circular RNA circFGFR1int2 up-regulates FGFR1 by recruiting transcriptional activators P65/FUS and suppressing miR-4687-5p to promote prostate cancer progression |
URI | https://www.proquest.com/docview/2902138530 https://search.proquest.com/docview/2892946166 https://doaj.org/article/3bf8f3c0d28646be98cfaf26d9a0b507 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZrC2MvZVfmtQsaDPYwRHxRZPtpJKNZGSSUbIGwF2HdSmCzPTsu5G_tF-4c2WnJw_biEEtygo90vu9I50LIe2AccazyiAkTThi3ScFy4RTTJlSRsUYpH8e9WIrrNf-6mWyGDbd2cKs86ESvqE2lcY98HOeARgmAS_ip_s2wahSerg4lNE7IWRxxPKY9m10tb1YP2fbA_DmEymRi3AK6gWIAnGIhamW2P4Ijn7X_X7rZA878KTkfmCKd9qJ9Rh7Z8jl5vBjOwl-QP1NaVnf2J92WfR0bqreN9yqlq-XUf5l_ma8iaI5pV7OmrzpvW-pvU7WnoO2abouOz3SHmHXQIPCzGO9whwZ5S2_EZDxff6NFaWjb1b3nLAz5tV0xLkB7TGq6q2jtHfssfvooJapxQjXUe4D12T9ekvX86vvnazZUYGAagH3HHNdCaOuA9cGr1ElinbAi5Q4sW2BKKkGMdyrSLio4WDIOqLouUgeDnQMyl7wip2VV2teEYlHjkBeZSSeCh04VPExyozKtDIZ9mYB8PAhC1n2iDekNlEzIXmwSxCa92OQ-IDOU1X1PTJLtb1TNrRzWnEyUy1yiQxNnggtl80y7wsXC5EWogAcH5ANKWuJShresiyEiAf4wJsWS0zRNwJwDShSQy6OesAT1cfNhrshBBbTyYcIG5N19M45Et7bSVh30yYCdchEJ8eb_j7ggT7DOPQZBxvElOd01nX0LbGinRuQk3aSjYeKP_J4CXBc8g-tq9uMvU0YODg |
link.rule.ids | 315,786,790,870,2115,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkYAL4qktLGAkJA7IahI7TnJCBVEKbCtUtlJvVvxClSAJSbtS_xa_kBkn3VUPcIoa20mVGX_zTTIPQl4D40gSXcRM2ihlwvGSFdJrZmykY-us1iGPe76Qs5X4sk7Xwwu3bgirPGBiAGpbG3xHPk4KsEYcjEv0rvnNsGsUfl0dWmjcJLcE5wL1PFtfO1wCnJ9Dokwuxx3YNoAFsFIsQkxm-yNjFGr2_wuZg7mZ3if3Bp5IJ71gH5AbrnpIbs-HL-GPyJ8JrepL95Nuqr6LDTWbNsSU0uViEn5MP02XMQwndNewtu857zoaTlO9p4B17W6DYc90ixbrgB9wW8x2uER3vKPfZDqerr7TsrK02zV93Cws-bVZMiEBO9KGbmvahLA-h8eQo0QNqlNLQ_xXX_vjMVlNP158mLGh_wIzYNa3zAsjpXEeOB88SsO589LJTHjwa4EnaY4W3uvY-LgU4Md4IOqmzDws9h6oHH9CTqq6cqeEYkvjSJS5zVIpIq9LEfHC6txoi0lfdkTeHgShmr7MhgruSS5VLzYFYlNBbGo_Iu9RVlczsUR2OFG3P9Sw4xTXPvfcRDbJpZDaFbnxpU-kLcpIAwsekTcoaYUbGZ6yKYd8BPjDWBJLTbKMgzMHhGhEzo5mwgY0x8MHXVEDAHTqWl1H5NXVMK7EoLbK1TuYkwM3FTKW8un_L_GS3JldzM_V-efF12fkLna8x3TIJDkjJ9t2554DL9rqF0H5_wJb0QvQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+novel+intronic+circular+RNA+circFGFR1int2+up-regulates+FGFR1+by+recruiting+transcriptional+activators+P65%2FFUS+and+suppressing+miR-4687-5p+to+promote+prostate+cancer+progression&rft.jtitle=Journal+of+translational+medicine&rft.au=Wang%2C+Ruyue&rft.au=Zhong%2C+Jinjing&rft.au=Pan%2C+Xiuyi&rft.au=Su%2C+Zhengzheng&rft.date=2023-11-22&rft.pub=BioMed+Central&rft.eissn=1479-5876&rft.volume=21&rft.spage=1&rft_id=info:doi/10.1186%2Fs12967-023-04718-y |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |